Trial · NCT01998438

Prospective Trial of Tranexamic Acid in Cardiac Surgery

NCT01998438, Phase 4, Completed, Hongwen Ji; results first posted 2016-02-26

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Prospective Trial of Tranexamic Acid in Cardiac Surgery. Trials, record NCT01998438. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01998438

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Prospective Trial of Tranexamic Acid in Cardiac Surgery
NCT number: NCT01998438
Status: Completed
Phases: Phase 4
Enrollment: 955 participants, actual
Lead sponsor: Hongwen Ji
Conditions: C.Surgical Procedure; Cardiac
Interventions: Tranexamic Acid
First posted: 2013-11-28
Last updated: 2016-02-26
Results first posted: 2016-02-26

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame
Primary	Postoperative Blood Loss	24hrs postoperatively
Secondary	Number of Participants Needs Allogenic Transfusion	on the 7th day postoperatively
Other	Rate of Reexploration for Bleeding	on the 7th day postoperatively

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Postoperative Blood Loss	24hrs postoperatively	ml	MEDIAN
SECONDARY	Number of Participants Needs Allogenic Transfusion	on the 7th day postoperatively
OTHER_PRE_SPECIFIED	Rate of Reexploration for Bleeding	on the 7th day postoperatively

Source ClinicalTrials.gov

Results by group3

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Postoperative Blood Loss	Small Dose	520	Inter-Quartile Range 350 to 690	ml
Postoperative Blood Loss	Medium Dose	490	Inter-Quartile Range 350 to 690	ml
Postoperative Blood Loss	Large Dose	450	Inter-Quartile Range 324.5 to 620	ml

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Small Dose	319
Overall Study	STARTED	Medium Dose	318
Overall Study	STARTED	Large Dose	318
Overall Study	COMPLETED	Small Dose	319
Overall Study	COMPLETED	Medium Dose	318
Overall Study	COMPLETED	Large Dose	318
Overall Study	NOT COMPLETED	Small Dose	0
Overall Study	NOT COMPLETED	Medium Dose	0
Overall Study	NOT COMPLETED	Large Dose	0

Source ClinicalTrials.gov

Adverse events12

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	wound infection	Infections and infestations	Small Dose	2	319	2
other	wound infection	Infections and infestations	Medium Dose	3	318	3
other	wound infection	Infections and infestations	Large Dose	2	318	2
serious	renal dysfunction	Renal and urinary disorders	Small Dose	30	319	30
serious	renal dysfunction	Renal and urinary disorders	Medium Dose	40	318	40
serious	renal dysfunction	Renal and urinary disorders	Large Dose	28	318	28
serious	usage of IABP	Cardiac disorders	Small Dose	2	319	2
serious	usage of IABP	Cardiac disorders	Medium Dose	1	318	1
serious	usage of IABP	Cardiac disorders	Large Dose	1	318	1
serious	cerebral embolism	Nervous system disorders	Small Dose	2	319	2

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Small Dose
Total, all-cause mortality	Medium Dose
Total, all-cause mortality	Large Dose
Total, other adverse events	Small Dose	2	319
Total, other adverse events	Medium Dose	3	318
Total, other adverse events	Large Dose	2	318
Total, serious adverse events	Small Dose	34	319
Total, serious adverse events	Medium Dose	42	318
Total, serious adverse events	Large Dose	29	318

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01998438

GET https://conductscience.org/api/trials/v1/NCT01998438/registered

API reference For AI assistants